GlassScriptPhysician profile
Fred L Hamlin
NPI 1194041897
$4,047.32
in general payments reported to CMS, 2019-2025
27 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $782 · 2023: $425 · 2024: $2,306 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133 · Travel and Lodging: $907 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.37 |
| Travel and Lodging | $907.47 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,784.73 | 2024 | Symplicity G3, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $636.79 | 2022-2025 | |
| Pfizer INC. | $292.95 | 2021-2025 | |
| Amgen INC. | $236.45 | 2021-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.63 | 2021-2024 | Lifevest |
| Novo Nordisk INC | $123.10 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $122.88 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $115.05 | 2022-2024 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.93 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $68.25 | 2022-2025 | Enroute Transcarotid Neuroprotection System, Bodyguardian |
| Bayer Healthcare Pharmaceuticals INC. | $50.15 | 2025 | |
| Kestra Medical Technology Services, INC. | $44.76 | 2025 | Assure Wcd |
| Chiesi USA, INC. | $44.16 | 2022 | |
| Inspire Medical Systems, INC. | $35.79 | 2024-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $34.83 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.75 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $29.74 | 2025 | Eliquis |
| Scpharmaceuticals INC. | $29.14 | 2023 | |
| Abbott Laboratories | $23.27 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $20.03 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $16.59 | 2021 | |
| Eagle Pharmaceuticals, INC. | $16.59 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.17 | 2021 | |
| Bard Peripheral Vascular, INC. | $14.73 | 2022 | |
| Esperion Therapeutics, INC. | $13.71 | 2022 | |
| Cvrx, INC. | $11.80 | 2023 | Barostim Neo System |
| Surmodics, INC. | $9.35 | 2024 | Pounce Thrombectomy, Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Hamlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.